Journal ArticleDOI
Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?
Lap Shu Alan Chan,Rena Buckstein,Marciano D. Reis,Alden Chesney,Adam Lam,Matthew C. Cheung,Eugenia Piliotis,Lilly Chunhong Gu,Richard A. Wells +8 more
Reads0
Chats0
TLDR
These results establish a relationship between CD34+ cell ROS content and serum ferritin concentration in MDS patients with iron overload, and indicate that iron chelation therapy in this patient population reverses this ROS accumulation.About:
This article is published in Blood.The article was published on 2008-11-16. It has received 18 citations till now. The article focuses on the topics: Haematopoiesis & Bone marrow.read more
Citations
More filters
Journal ArticleDOI
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
Roberto Guariglia,Maria Carmen Martorelli,Oreste Villani,Giuseppe Pietrantuono,Giovanna Mansueto,Fiorella D'Auria,Vitina Grieco,Gabriella Bianchino,Rosa Lerose,Giovanni Battista Bochicchio,Pellegrino Musto +10 more
TL;DR: The literature about this phenomenon is reviewed and the possible biological mechanisms underlying hematologic effects of deferasirox in MDS are discussed, starting from a new paradigmatic case in whom both hemoglobin level and platelet count improved, inducing transfusion-independence, soon after starting the treatment with defer asirox.
Journal ArticleDOI
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Heather A. Leitch,Ambica Parmar,Richard A. Wells,Lisa Chodirker,Nancy Zhu,Thomas J. Nevill,Karen W.L. Yee,Brian Leber,Mary-Margaret Keating,Mitchell Sabloff,Eve St. Hilaire,Rajat Kumar,Robert Delage,Michelle Geddes,John M. Storring,Andrea Kew,April Shamy,Mohamed Elemary,Martha Lenis,Alexandre Mamedov,Jessica Ivo,Janika Francis,Liying Zhang,Rena Buckstein +23 more
TL;DR: In this prospective, non‐randomized analysis, receiving ICT was associated with superior OS in lower IPSS risk MDS, adjusting for age, frailty, comorbidity, disability, revised IPSS, TD severity, time to TD and receiving disease‐modifying agents.
Journal ArticleDOI
Controversies surrounding iron chelation therapy for MDS.
TL;DR: Data on the impact of IOL in MDS and SCT, possible mechanisms of iron toxicity such as oxidative stress, and the impactof lowering iron on organ function and survival are reviewed are reviewed.
Journal ArticleDOI
Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome
TL;DR: Twenty-nine other MDS patients reported showing improvement in hemoglobin level with iron chelation; nine became transfusion independent, nine had decreased transfusion requirements, and some showed improved trilineage myelopoiesis.
Journal ArticleDOI
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
TL;DR: The authors summarize the current knowledge regarding IO in MDS and the role of ICT and suggest that iron chelation therapy (ICT) remains a very controversial aspect in the management of MDS.